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Background: Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by vasculopathy, inflammation, and extensive fibrosis of the skin
and organs. Exosomes (EXOs) are cell-derived vesicles 30-150 nm in
size that contain various mRNAs, microRNAs and proteins.
Objectives: Here, we aimed to investigate the roles of EXOs in SSc
pathogenesis, especially in angiogenesis.
Methods: EXOs were respectively isolated from plasma, cultured periph-
eral blood mononuclear cells (PBMCs) and neutrophil supernatants, and
were identified by transmission electron microscopy. The expression of
S100A8/A9 was measured by real-time PCR and ELISA. Proliferation,
migration and scratch assays in human dermal microvascular endothelial
cells (HDMECs) were used to study the influence of neutrophil EXOs
and neutrophil EXOs S100A8/A9. We also performed a genome-wide
transcriptome analysis on PBMCs from 19 SSc patients and 18 matched
normal controls (NC) using Illumina BeadChip arrays. The ingenuity path-
way analysis (IPA) tool and Database for Annotation, Visualization and
Integrated Discovery (DAVID) were used for bioinformatics analysis.
Results: Plasma EXOs and neutrophil EXOs from SSc patients sup-
pressed the proliferation and migration of HDMECs. Using a microarray
analysis we found 28% genes upregulated in PBMCs could exist in
EXOs, especially the S100 protein family, including S100A8/A9. High lev-
els of S100A8/A9 were consistently verified in SSc plasma, PBMCs,
plasma EXOs, PBMC EXOs and neutrophil EXOs. Particularly, S100A8/A9
expression in neutrophil EXOs was distinctly higher than that in PBMC
EXOs in SSc patients. Furthermore, we found that neutrophil EXOs
S100A8/A9 inhibit the proliferation and migration of HDMECs, and that
might through Toll-like receptor 4 (TLR4) pathway.
Conclusion: S100A8/A9 is one of components of neutrophil EXOs that
regulates vascular endothelial cell angiogenesis in SSc patients, most
likely by activating the TLR4 signalling pathway.
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Background: The treatment of systemic sclerosis (SSc) is a clinical chal-
lenge because of its complex pathogenesis. The rationale for the use of
rituximab (RTX), able to downregulate the B-cell over expression, is dem-
onstrated in different autoimmune diseases, some reports have suggested
its key role in regulating both vascular, fibrotic, and immune T- and B-
lymphocyte-mediated alterations that characterize several SSc manifesta-
tions. According to our previous experience with RTX [1], we suggested
a possible therapeutical role of RTX in SSc, along with its good safety
profile.
Objectives: To investigate the role and efficacy of RTX in our SSc
patients’ series.
Methods: A series of 24 SSc patients (M/F 7/17, mean age 55.2
±14.7SD years, mean disease duration 11.7± 7.3SD years, L/D cutaneous
subsets 11/13) were treated with one or more cycles of RTX (4 weekly
infusions of 375 mg/m2) and evaluated during a mean follow-up period of
12.3 ± 6.6SD years, range 2-26 years. The indications to RTX were
interstitial lung disease, cutaneous, articular manifestations, evaluating its
effects after 6 months of the first cycle and at the end of follow-up.
Results: After the first 6 months the extent of skin sclerosis measured
with modified Rodnan skin score (mRSS) significantly improved (from
16.3±9.8 to 12.3±7.1; p<0.0001), and remained stable at the end of the
follow-up (11.0±6.9; p=0.105). The effect on skin sclerosis was more evi-
dent in patients with diffuse cutaneous SSc (n=13) showing a significant
decrease of mRSS after the first 6 months (from 24.3± 5.4 to 17.9±4.3;
p=0.006) and at the end of the follow-up period (17.8±5.7; p=0.005).
Similarly, a valuable improvement of other skin manifestations, namely
hypermelanosis (17/20 pts), pruritus (18/21 pts), digital ulcers (8/18 pts)
and calcinosis (6/3 pts), was observed. Moreover, arthritis revealed a
good response to RTX treatment leading to a clear-cut reduction of swol-
len (from 2.0±2.8 to 0.3±1.3; p<0.0001) and tender joints (from 5.2±4.0
to 0.9±2.5; p<0.0001) in 20/24 patients. Finally, lung fibrosis detected in
19/24 on chest-CT remained stable during the entire follow-up, as well
as pulmonary function tests (PFTs). These positive clinical changes were
mirrored by the subjective improvement of patients‘ well being in all sub-
jects (HAQ from 1.04±0.55 to 0.85±0.38; VAS from 71.0±15.2 to 28.0
±10.3, p<0.0001). No significant side effects were observed during the
entire follow-up. Only in one patient a severe urinary tract infection lead-
ing to the discontinuation of the treatment was detected.
Conclusion: The present study reinforces the previous trials and our
preliminary researches on this topic, showing the efficacy of RTX in the
management of SSc with good safety profile. The specific therapeutical
role of RTX on B-cell-driven autoimmunity, might explain its beneficial
effects on some SSc clinical alterations. The improvement of skin sclero-
sis, articular symptoms and the stabilization of lung involvement were
identified as the main results. Further exploration of the potential clinical
efficacy of RTX in SSc with multicentre, double blind, controlled study is
needed.
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Background: Systemic sclerosis (SSc) can affect multiple organ systems
including the kidney. Renal disease, especially chronic kidney disease
(CKD), remains an important cause of morbidity and mortality in SSc.
The spectrum of renal complications in SSc include scleroderma renal cri-
sis (SRC), normotensive renal crisis, antineutrophil cytoplasmic antibody
associated glomerulonephritis, penicillamine-associated renal disease, and
reduced renal functional reserves. Furthermore, subclinical renal impair-
ment affects approximately 10-55% of SSc patients and might be associ-
ated with other vascular manifestations. However, the available evidence
on CKD in patients with SSc residing in low-middle income countries
(LMIC) is scarce. Because the health system of LMIC, and especially
Peru, could have great differences in access to diagnosis and manage-
ment of SSc, it is important to identify which clinical factors would be
associated with CKD in patients with this autoimmune disease.
Objectives: To identify the associated factors to renal involvement in
Peruvian patients with SSc.
Methods: We analyzed the associated factors to renal involvement in
SSc patients at Hospital Nacional Edgardo Rebagliati Martins Lima-Peru,
a national reference hospital in Peru. Between June 2001 and December
2018, we included ambulatory patients, older than 18-year-old with SSc
that met the ACR-EULAR classification criteria. In patients who accepted
to get informed consent, a complete clinical assessment and a sociode-
mographic survey were done. Additional clinical data were collected from
their clinical records. Multiple Poisson regression with robust standard
errors was used to identify significant and independently associated fac-
tor. Two models were estimated: one based on theoretically selected vari-
ables and another parsimonious model based on variables that was
selected using a manual backward selection procedure with a predeter-
mined alpha of 0.2. Adjusted prevalence ratio (aPR), 95% confidence
interval and p-values were reported.
Results: One hundred and five patients with SSc were included in this
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